These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19769740)

  • 1. Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer.
    Dang Y; Disis ML
    Ann N Y Acad Sci; 2009 Sep; 1174():81-7. PubMed ID: 19769740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen choice in adoptive T-cell therapy of cancer.
    Offringa R
    Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N; Zoernig I; Jäger D
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy of cancer: accomplishments and prospects.
    Rosenberg SA
    Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer.
    Gomez GG; Hutchison RB; Kruse CA
    Cancer Treat Rev; 2001 Dec; 27(6):375-402. PubMed ID: 11908930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-associated antigens and biomarkers in cancer and immune therapy.
    Malyankar UM
    Int Rev Immunol; 2007; 26(3-4):223-47. PubMed ID: 17558745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
    Peres E; Wood GW; Poulik J; Baynes R; Sood S; Abidi MH; Klein J; Bhambhani K; Dansey R; Abella E
    Neuropediatrics; 2008 Jun; 39(3):151-6. PubMed ID: 18991194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic T-lymphocyte-associated antigen-4.
    Hodi FS
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5238-42. PubMed ID: 17875750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of signal transduction in T cells from cancer patients.
    Ochoa AC; Longo DL
    Important Adv Oncol; 1995; ():43-54. PubMed ID: 7672813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological Response Modifiers Programme and cancer chemotherapy.
    Oldham RK
    Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we develop biomarkers that predict response of cancer patients to immunotherapy?
    Bonavida B; Huerta-Yepez S; Goodglick L; Mizutani Y; Miki T
    Biomarkers; 2005 Nov; 10 Suppl 1():S69-76. PubMed ID: 16298914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.
    Kakimi K; Nakajima J; Wada H
    Lung Cancer; 2009 Jul; 65(1):1-8. PubMed ID: 19062127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring cellular immune responses to cancer immunotherapy.
    Morse MA; Clay TM; Hobeika AC; Mosca PJ; Lyerly HK
    Curr Opin Mol Ther; 2001 Feb; 3(1):45-52. PubMed ID: 11249731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy].
    Van den Eynde B
    Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical development of T cell receptor gene therapy.
    Bendle GM; Haanen JB; Schumacher TN
    Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
    Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
    Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the efficacy of cancer immunotherapy.
    Copier J; Dalgleish AG; Britten CM; Finke LH; Gaudernack G; Gnjatic S; Kallen K; Kiessling R; Schuessler-Lenz M; Singh H; Talmadge J; Zwierzina H; Håkansson L
    Eur J Cancer; 2009 May; 45(8):1424-31. PubMed ID: 19167214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Universal and stemness-related tumor antigens: potential use in cancer immunotherapy.
    Parmiani G; Russo V; Marrari A; Cutolo G; Casati C; Pilla L; Maccalli C; Rivoltini L; Castelli C
    Clin Cancer Res; 2007 Oct; 13(19):5675-9. PubMed ID: 17908956
    [No Abstract]   [Full Text] [Related]  

  • 20. Making and circumventing tolerance to cancer.
    Kammertoens T; Blankenstein T
    Eur J Immunol; 2009 Sep; 39(9):2345-53. PubMed ID: 19634191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.